Table 1.
| lncRNA | Name | Alias | Chromosom e location: (strand) |
NCBI /ENSMBL |
Expression pattern |
Functional /clinical info |
|---|---|---|---|---|---|---|
| AB073614 [13] | NA | NA | Chr3:148891375-148893279(−) | NA | Up | Tumorigenesis, poor prognosis (OS) |
| AL132709.8 [4] | NA | NA | Chr14q32.31 | NA | Recurrence marker | |
| AC104699.1.1 [14] | NA | NA | NA | NA | Predictive survival | |
| ANRIL [15] | Antisense noncoding RNA in the INK4 locus (ANRIL) | CDKN2B-AS1; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089 | Chr9:21994778-22121097(+) | NR_003529 | Up | Metastasis, poor prognosis-survival |
| ASAP1-IT1 [16] | ASAP1 intronic transcript 1 | ASAP1-IT; ASAP1IT; DDEF1IT1; HSPC054; NCRNA00050 | Chr8:130295355-130296533(−) | NR_002765 | Fav OS | |
| BACE1-AS [17] | β-site APP cleaving enzyme-1 antisense strand | BACE1-AS1; NCRNA00177 | Chr11:117291346-117292170(+) | NR_037803 | Down | Tumor suppressor |
| BCYRN1 [22] | Brain cytoplasmic RNA1 | BC200; BC200a; LINC00004; NCRNA00004 | ChrX:70430,035-70948962(−) | NR_001568; AF20057 | Up and down | Tumor suppressor |
| CCAT1 [20] | Colon cancer associated transcript 1 | CARLo-5 | Chr8:127207866-127219088(??) | NR_108049 | Down | Metastatic |
| CCAT2 [19] | Colon cancer associated transcript 2 | NCCP1; LINC00873 | Chr8:127400399-127402150(+) | NR_109834 | Up | Short OS and DFS, positive with tumor grade and distant metastasis |
| CRNDE [21] | NA | NA | Chr16:54845189-5492918912(−) | ENST00000613942 | High | Oncogenic, poor prognosis |
| FALEC [18] | Focally amplified long noncoding RNA in epithelial cancer | FAL1 | Chr1:150488233-150490508(+) | NR_051960 | Up | |
| FAM215A [16] | Family with sequence similarity 215 member A | APR-2; C17orf88; LINC00530 | Chr17:43917208-43917987(+) | NR_026770 | Up | Fav OS |
| GACAT3 [23] | Gastric cancer associated transcript 3 | LINC01458; lncRNA-AC130710 | Chr2:16050427-16085689(+) | NR_126559 | Nonequivalent outcome | |
| GAS5 [54,56] | Growth arrest specific 5 | GAS5; SNHG2; NCRNA00030 | Chr1:173863900-173868882(−) | NR_002578 | Down | |
| H19 [20,39,54,56] | H19, imprinted maternally expressed transcript | ASM; ASM1; BWS; D11S813E; LINC00008; NCRNA00008; WT2 | Chr11:1995163-2001470(−) | NR_131223 | Up | Tumorigenesis, recurrence marker, metastasis |
| HOST2 [29] | Human ovarian-cancer-specific transcript 2 | CERNA2 | Chr10:84167228-84172076(−) | NR_134505 | Up or down | Risk factor |
| HOTAIR [28,35,40,43,44] | HOX transcript antisense RNA | HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 | Chr12:53962308-53974956(−) | NR_003716 | Up/differential | Prognostic metastatic marker |
| HOXA11-AS [46] | HOXA11 antisense RNA | HOXA-AS51; HOXA11AS; HOXA11S; NCRNA00076; HOXA11-AS | Chr7:27185408-27189293(+) | NR_002795 | Down | Oncogenic |
| HOTAIRM1 [4] | HOXA transcript antisense RNA, myeloid-specific 1 | HOXA1-AS1; HOXA-AS1; NCRNA00179 | Chr7:27135713-27139877(−) | NC_000007.14 | Recurrence marker | |
| LINC00472 [16] | Long intergenic non-protein-coding RNA 472 | C6orf155 | Chr6:71407864-71420745(−) | NR_121612 | Fav OS | |
| LINC00515 [54] | NA | LINC00515; PRED21; C21orf71 | Chr21:25582770-25583326(−) | ENSG00000260583 | Down | |
| LINC00961 [54] | NA | NA | Chr9: 35909483-35937153(+) | ENSG00000235387 | Up | |
| linc-CARS2-2 [54] | Cysteinyl-tRNA synthetase 2, mitochondrial | FLJ12118 | Chr13:110641584-10644681(−) | ENST00000542774 | Up | |
| lin-RECK-3 [54] | reversion inducing cysteine rich protein with kazal motifs | ST15, hRECK | Chr9:36036924-36086181(+) | ENST00000475774 | Up | |
| linc-TNFRSF19-1 [54] | TNF receptor superfamily member 19 | TAJ-alpha, TROY, TAJ, TRADE | Chr13:23579359-23594411(+) | ENST00000464735 | Down | |
| LOC100128881 [20] | VPS9D1 antisense RNA1 | LOC100128881; VPS9D1-AS1 | Chr16:89711856-89718165(+) | NR_036480 | Down | Metastasis |
| LOC100190986 [4] | Uncharacterized | NA | Chr16:21432003-21434455(−) | NA | Recurrence marker | |
| LOC100292680 [20] | Long intergenic non-protein-coding RNA 942 | LOC100292680; LINC00942 | Chr12:1500525-1507318(−) | NR_028415 | Down | |
| LSINCT5 [49] | Long stress-induced noncoding transcript 5 | NA | Chr5:2712591-2715237(−) | NR_145480 | Up | |
| LUCAT1 [54] | Lung cancer associated transcript 1 | LUCAT1; SCAL1 | Chr5:91303029-91314402(−) | NR_103548 | Up | |
| MALAT1 [4,20,27,33,41,55,57] | Metastasis-associated lung adenocarcinoma transcript 1 | HCN; LINC00047; NCRNA00047; NEAT2; PRO2853 | Chr11:65497679-65504494(+) | NR_002819 | Up | Recurrence marker |
| MEG3 [48,51,53] | Maternally expressed 3 | FP504; GTL2; LINC00023; NCRNA00023; PRO0518; PRO2160; onco-lncRNA-83; prebp1 | Chr14:100826108-100861026(+) | NR_046472 | ||
| MIR22HG [36] | NA | C17orf91 | Chr17:1711504-1716272(−) | NR_028502 | Oncogene, prognostic marker | |
| MNX1-AS1 [20] | MNX1 antisense RNA 1 | CCAT5; MNX1-AS1; LOC645249 | Chr7:157010805-157016426 ?? | NR_038835 | Down | |
| NEAT1 [8,26] | Nuclear paraspeckle assembly transcript 1 | LINC00084; NCRNA00084; TncRNA; VINC | Chr11:65422798-65445540(+) | NR_131012 | Clinical biomarker | |
| NRCP [47] | NA | NA | NA | NA | ||
| OVAAL [24] | Ovarian adenocarcinoma-amplified long noncoding RNA | LINC01131; OVAL | Chr1:180558974-180566518(+) | NR_125716 | ||
| P15INK4B [15] | Cyclin-dependent kinase inhibitor 2B | P15; MTS2; TP15; CDK4I; INK4B; p15INK4b; CDKN2B | Chr9:22002903-22009363(−) | ENSG00000147883 | Down | |
| PTPRD-AS1 [23] | PTPRD antisense RNA1 | Chr9:8858018-8861727(+) | NR_121600 | Nonequivalent outcome | ||
| PVT1 [31,37,38] | Pvt1 oncogene | LINC00079; MYC; NCRNA00079; onco-lncRNA-10; PVT1; LINC00079; NCRNA00084 | Chr8:127794533-128101253(+) | NR_003367 | Up | Oncogene |
| RP1-223E5.4 [23] | NA | AL441883.1 | Chr6:13614111-13615155(−) | ENST00000566170NOTFOUND | Nonequivalent outcome | |
| RP4-799P18.3 [23] | NA | AL122008.4 | Chr1:234268583-234272500(−) | ENST00000446433 | Nonequivalent outcome | |
| RP11-254122.1 [23] | NA | MIR583HG | Chr5:96050115-96215519(+) | ENST00000507997 | Nonequivalent outcome | |
| RP11-284N8.3.1 [14] | NA | NA | NA | NA | Predictive survival | |
| RP11-307C12.11 [23] | NA | DCST1-AS1 | Chr1:155045191-155046118(−) | ENST00000452962 | Nonequivalent outcome | |
| RP11-57P19.1 [23] | NA | AC009432.1 | Chr15:94600014-94600821(+0 | ENST00000560391 | Nonequivalent outcome | |
| RP11-80H5.7 [23] | NA | AL157400.4 | Chr10:89694295-89697928(−) | ENST00000455699 | Nonequivalent outcome | |
| RUNX1-IT1 [4] | NA | Chr21q22.12 | NA | Recurrence marker | ||
| TC0100223 [45] | NA | NA | NA | NA | Down | |
| TC0101441 [42,45] | NA | NA | Chr1:202377159-202378011 | NA | Down | Prognostic factor OS |
| TC010686 [45] | NA | NA | Chr1:244341256-244343791 | NA | Up | |
| TC1500845 [45] | NA | NA | Chr15:38773376-38774597 | NA | Up | |
| TUG1 [34] | Taurine upregulated 1 | LINC00080; NCRNA00080; TI-227H | Chr22:30969211-30979395(+) | NR_002323 | ||
| UCA1 [20,50,52] | Urothelial cancer associated 1 | CUDR; LINC00178; NCRNA00178; UCAT1; onco-lncRNA-36 | Chr19:15828947-15836321(+) | NR_015379 | Down | |
| XIST [32] | X inactive specific transcript | DXS1089; DXS399E; LINC00001; NCRNA00001; SXI1; swd66 | ChrX:73820651-73852753(−) | NR_001564 | Down | |
| ZNF300P1 [30] | NA | NA | Chr5:150930645-150946289(−) | ENST00000356555 |